Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Jul 24;99(30):e21402.
doi: 10.1097/MD.0000000000021402.

A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019

Xuemei Wang  1 , Ping Xie  2 , Guojuan Sun  1 , Min Zhao  1 , Zhumei Deng  1 , Yunxia Zhou  1 , Shuting Bao  1
Affiliations
Meta-Analysis

A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019

Xuemei Wang et al. Medicine (Baltimore). .

Erratum in

  • Study Protocol Titles: Erratum.
    [No authors listed] [No authors listed] Medicine (Baltimore). 2020 Aug 14;99(33):e21984. doi: 10.1097/MD.0000000000021984. Medicine (Baltimore). 2020. PMID: 32872085 Free PMC article. No abstract available.

Abstract

Background: Coronavirus disease 2019 (COVID-19) is highly contagious, and the epidemic has spread to hundreds of countries around the world, and seriously threatens the life safety of people around the world. Arbidol is an antiviral drug with high potential against COVID-19, but evidence of effectiveness and safety is lacking. The systematic review protocol aims to formulate a research plan that can evaluate the efficacy and safety of arbidol for COVID-19.

Methods: The retrieval time will be from the database establishment to June 2020. The retrieval database will include the Cochrane Library, PubMed, Embase, OVID, CNKI, Wanfang, VIP, CBM, etc. The primary outcome will be clinical efficacy, and the secondary results will be accompanying symptoms, time for the temperature to return to normal, time of novel coronavirus nucleic acid turning negative, blood sample test, Computed Tomography examination, length of hospitalization, adverse reactions, and adverse events. RevManV.5.3 software will be used for meta-analysis, and fixed effects model, random-effects model, subgroup analysis, and descriptive analysis will be adopted according to the heterogeneity of the research results.

Results: To provide the latest evidence of clinical efficacy and safety of arbidol in the treatment of COVID-19.

Conclusion: Our study will provide the latest evidence analysis of the efficacy and safety of arbidol for COVID-19, to provide evidence-based medicine for the prevention and control of this epidemic.

Registration details: PROSPERO CRD42020189203.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
The PRISMA flow diagram of literature screening process. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
See this image and copyright information in PMC

References

    1. Jiang F, Deng L, Zhang L, et al. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Int Med 2020;35:1545–9. - PMC - PubMed
    1. Shi Y, Wang G, Cai XP, et al. An overview of COVID-19. J Zhejiang Univ Sci B 2020;21:343–60. - PMC - PubMed
    1. Sifuentes-Rodríguez E, Palacios-Reyes D. COVID-19: the outbreak caused by a new coronavirus. Bol Med Hosp Infant Mex 2020;77:47–53. - PubMed
    1. Zhai P, Ding Y, Wu X, et al. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020;55:105955. - PMC - PubMed
    1. Zhou Y, Zhang S, Chen J, et al. Analysis of variation and evolution of SARS-CoV-2 genome. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:152–8. - PMC - PubMed